Results 191 to 200 of about 326,864 (305)

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden   +3 more
wiley   +1 more source

Early-stage environmental impact forecasting of chemicals and processes with machine learning and data analytics tools. [PDF]

open access: yesClean Technol Environ Policy
Appiah HD   +5 more
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran   +5 more
wiley   +1 more source

Use of antiemetics in early pregnancy 2012–2022: A cross‐sectional study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Nausea and vomiting in pregnancy impact quality of life, yet many pregnant women feel dismissed by healthcare professionals, despite the safety of first‐line antiemetic treatments for both mother and fetus. Therefore, this study aims to describe the prevalence of patient‐reported antiemetic use in early pregnancy in Copenhagen, Denmark, the changes
Katrine Bak Wraae   +6 more
wiley   +1 more source

Potential for use of Al/machine learning for pharmacovigilance: Is there a role for regulators?

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
Christina Gao   +3 more
wiley   +1 more source

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy